Kevin R. Herbert
Known title: EVP & President, North AmericaCIK: 0001984826
Associated companies
Transaction History
| NATR | ▼ Sell | Tax Withholding | 1,976 | $42K | 6/26/2026 | View on chart |
| NATR | ▼ Sell | Open Market | 1,134 | $23K | 6/12/2026 | View on chart |
| NATR | ▼ Sell | Open Market | 866 | $18K | 6/12/2026 | View on chart |
| NATR | ▲ Buy | Grant | 8,326 | $0 | 5/15/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 1,500 | $0 | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 366 | $9K | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 917 | $23K | 3/11/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,163 | $29K | 3/10/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 1,239 | $0 | 3/6/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 368 | $9K | 3/6/2026 | View on chart |
| NATR | ▼ Sell | Other | 7,124 | — | 3/6/2026 | View on chart |
| NATR | ▲ Buy | Grant | 7,124 | $179K | 3/6/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 980 | $14K | 3/11/2025 | View on chart |
| NATR | ▲ Buy | Grant | 11,760 | $173K | 3/10/2025 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 2,406 | $36K | 6/26/2024 | View on chart |
| NATR | ▲ Buy | Grant | 9,905 | $0 | 3/11/2024 | View on chart |
| NATR | ▲ Buy | Grant | 24,336 | $0 | 7/11/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nature's Sunshine Q2 Earnings Reviewed Against Peers
A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.
Nature's Sunshine Q2 Earnings Reviewed Against Peers. A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.